At Cellebration, we have mastered the technology for isolating a maximum number of viable stem cells from either autologous (own) cells or allogeneic (donor) cells to treat patients with Diabetes Type 1.
These cells are administered through one of the following methods after a considerable analysis of the patient’s unique history:
In this mode, cells are infused directly at the targeted site through a catheter-based delivery mode.
In this delivery mode, cells are infused into the peripheral veins to expand blood volumes in the system, to ensure that the maximum number of cells are reaching the targeted area.
Once infused back in the body, these cells can be repopulated at the damaged parts of the pancreas. Through their strong paracrine effects, they differentiate into insulin producing beta cells and initiate secretions as new cells.